Abstract

An innovativevay to cool the crystalloid cryoprotectivecardioplegic solution during open heart surgery

A new crystalloid cryoprotectivecardioplegic solution was invented in Turkmenistan in 2020, which can withstand  cooling down to -5, -7 degrees.This is the first and only solution with a unique property to cool the myocardium to  +5, +3 degrees at a minimum calculated dose of 7,5 ml/kg of patient weight. After clamping the aorta, the effect of  the injection of this solution into the coronary arteries occurs in the first 35-40 seconds through bradycardia, after  which a stable asystole occurs for more than 70 minutes. If it is necessary to extend the time of myocardial protection  to 120 minutes, it is necessary to inject half the calculated dose of this solution. The restoration of the heart rhythm  after removing the clamp from the aorta occurs within 3 - 4 minutes independently through bradycardia (junctional  rhythm) or through high-wave fibrillation without cardioversion and the introduction of cardiotonics. This  solution works due to the cryoprotective effect with conformational flexibility and sufficient refrigeration capacity.  Histological examinations after 60 and 120 minutes of myocardial cardioplegia showed edema in 25% and 45%  of cardiomyocytes, respectively. After 15-30 minutes of myocardial reperfusion (after removing the clamp from the  aorta), the edema of the cardiomyocytes disappears. The method of cooling the crystalloid cryoprotectivecardioplegic  solution below 0 degrees and its composition are protected by patent No.819 dated 02/18/2020.It is a simple,  convenient, reliable and practical "cryoprocard" solution with an economical 500 ml package.


Author(s):

Gurdov Shatlyk



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+

paper.io

agar io

wowcappadocia.com
cappadocia-hotels.com
caruscappadocia.com
brothersballoon.com
balloon-rides.net

wormax io